{"id":7373,"date":"2025-10-30T13:08:22","date_gmt":"2025-10-30T12:08:22","guid":{"rendered":"https:\/\/www.msd.ch\/de\/?post_type=story&p=7373"},"modified":"2025-10-30T13:09:28","modified_gmt":"2025-10-30T12:09:28","slug":"wir-unterstutzen-den-brustkrebsmonat-oktober","status":"publish","type":"story","link":"https:\/\/www.msd.ch\/de\/stories\/wir-unterstutzen-den-brustkrebsmonat-oktober\/","title":{"rendered":"Wir unterst\u00fctzen den Brustkrebsmonat Oktober"},"content":{"rendered":"\n
\n
\n \n \n Unsere Mitarbeitenden<\/small>\n <\/a>\n \n \n

\n Wir unterst\u00fctzen den Brustkrebsmonat Oktober\n <\/h1>\n

Wussten Sie, dass Brustkrebs die h\u00e4ufigste Krebsart bei Frauen ist? Bei MSD zeigen wir Solidarit\u00e4t mit Menschen, die von Brustkrebs betroffen sind, und tun alles, was wir k\u00f6nnen, um weitere Fortschritte bei der Bek\u00e4mpfung der Krankheit zu unterst\u00fctzen. Insbesondere w\u00e4hrend des Brustkrebsmonats Oktober unterst\u00fctzen wir verschiedene Aktivit\u00e4ten, um \u00fcber die Bedeutung von Pr\u00e4vention und Fr\u00fcherkennung aufzukl\u00e4ren. Erfahren Sie mehr \u00fcber unser Engagement.<\/p>\n <\/div>\n\n

\n

30.10.2025<\/p>\n

\n

Share this article<\/p>\n

\n \nFacebook icon<\/title><\/svg>\n<\/a><\/p>\n

\n\n\n\n\t.st0{fill:#00857C;}\n\n\nX icon<\/title><\/svg>\n<\/a><\/p>\n

\n \nLinkedin icon<\/title><\/svg>\n<\/a><\/p>\n

\n \nEmail icon<\/title><\/svg>\n<\/a><\/p>\n <\/div>\n <\/div>\n\n
\n
\n
\n \n \n \n \n \"Banner:\n <\/picture>\n\n <\/figure>\n \n <\/div>\n <\/div>\n\n
\n
\n
\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n\n\n

<\/p>\n\n\n\n

<\/div>\n\n\n\n

In der Schweiz wird jedes Jahr bei rund 6’600 Frauen und 60 M\u00e4nnern Brustkrebs diagnostiziert. Obwohl neue Therapien die Prognose von Brustkrebspatient:innen verbessert haben, sterben in der Schweiz immer noch rund 1\u2019400 Frauen pro Jahr an der Krankheit.<\/p>\n\n\n\n

\u00abWir stehen hinter den M\u00fcttern, Schwestern, T\u00f6chtern und Angeh\u00f6rigen, die von Brustkrebs betroffen sind, und setzen alles daran, weitere Innovationen voranzutreiben, die helfen, Leben zu retten und zu verbessern.\u00bb<\/em><\/em><\/p>\n\n\n\n

Wie bei vielen anderen Krebsarten gilt auch bei Brustkrebs: Je fr\u00fcher er erkannt wird, desto besser sind die Heilungschancen.<\/strong> <\/strong>Deshalb unterst\u00fctzen wir verschiedene Aufkl\u00e4rungsaktionen.<\/p>\n\n\n\n

<\/div>\n\n\n\n
\n
\n

Aufkl\u00e4rungsaktion im Pink Cube<\/strong><\/strong><\/strong><\/p>\n\n\n\n

Im Oktober unterst\u00fctzen wir die Aufkl\u00e4rungsaktion \u00abPINK CUBE Test Your Breast\u00bb mit EUROPA DONNA Schweiz und der Krebsliga Schweiz und vielen weiteren Sponsoren.<\/p>\n\n\n\n

Durch 11 Kantone reist der pinke Container \u00abPink Cube\u00bb, wo Frauen\u00e4rzt:innen interessierten Besucher:innen eine kostenlose Beratung und Tastuntersuchung der Brust anbieten. Jede\/r ist eingeladen, den Pink Cube zu besuchen.<\/p>\n\n\n\n

Weitere Informationen<\/a><\/strong><\/p>\n<\/div>\n\n\n\n

\n
\"Photo:<\/figure>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n
\"Banner:<\/figure>\n<\/div>\n\n\n\n
\n

Website \u00fcber Brustkrebs<\/strong><\/strong><\/p>\n\n\n\n

Unser Patientenportal MSD Gesundheit enth\u00e4lt ausf\u00fchrliche Informationen \u00fcber Brustkrebs, einschliesslich Risiken und M\u00f6glichkeiten zur Pr\u00e4vention, Fr\u00fcherkennung und Behandlung. Dar\u00fcber hinaus bietet die Website Antworten auf die h\u00e4ufigsten Fragen \u00fcber Brustkrebs und Informationen dar\u00fcber, wo Betroffene Rat und Unterst\u00fctzung finden k\u00f6nnen.<\/p>\n\n\n\n

Besuchen Sie das MSD Patientenportal<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n

Pink Ribbon Charity Walk<\/strong><\/p>\n\n\n\n

Ein besonderer Moment f\u00fcr uns! Jedes Jahr nehmen mehr als 50 Kolleg:innen als MSD Schweiz Team am Pink Ribbon Charity Walk teil.
Der Solidarit\u00e4tslauf ehrt die \u00dcberlebenden, erinnert an diejenigen, die wir verloren haben, sch\u00e4rft das Bewusstsein und sammelt dringend ben\u00f6tigte Gelder, um auf die Vision hinzuarbeiten, dass niemand mehr an \u00a0Brustkrebs stirbt.<\/p>\n<\/div>\n\n\n\n

\n
\"MSD<\/figure>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

Fakten \u00fcber Brustkrebs, die Sie wissen sollten<\/strong><\/strong><\/p>\n\n\n\n

Brustkrebs ist die h\u00e4ufigste Krebsart bei Frauen und macht fast ein Drittel aller Krebsdiagnosen aus. In der Schweiz erkranken j\u00e4hrlich rund 6’600 Frauen und 60 M\u00e4nner an Brustkrebs, und rund 1’400 Frauen sterben j\u00e4hrlich daran. Die Erkrankungsrate nimmt mit dem Alter zu. Dennoch ist jede f\u00fcnfte Frau zum Zeitpunkt der Diagnose j\u00fcnger als 50 Jahre. Die Mammografie ist die wichtigste Untersuchung zur Fr\u00fcherkennung von Brustkrebs. Sie kann einen Tumor sichtbar machen, bevor er tastbar wird oder Beschwerden verursacht. Fachgesellschaften und die Krebsliga empfehlen Frauen ab 50 alle zwei Jahre eine Mammografie durchzuf\u00fchren. Das regelm\u00e4ssige Abtasten der Brust tr\u00e4gt dazu bei, das K\u00f6rpergef\u00fchl zu schulen und Ver\u00e4nderungen zu erkennen, die \u00e4rztlich kontrolliert werden sollten.<\/p>\n\n\n\n

Je fr\u00fcher Brustkrebs erkannt und behandelt wird, desto besser sind die Heilungschancen. <\/strong>Das ist die Botschaft, die wir allen vermitteln wollen!<\/p>\n\n\n\n

<\/div>\n\n\n\n

\u00dcber unsere klinische Forschung in der Onkologie<\/strong><\/strong><\/p>\n\n\n\n

Wussten Sie, dass MSD eines der weltweit gr\u00f6ssten und am schnellsten wachsenden klinischen Forschungsprogramme im Bereich der Onkologie betreibt? Es umfasst derzeit mehr als 1\u2019600 klinische Studien. Die Schweiz ist Teil dieses Forschungsprogramms. Unser Team koordiniert derzeit 36 klinische Studien in verschiedenen Krebserkrankungen (Stand: 10\/2025). MSD ist auch eines der f\u00fchrenden Unternehmen bei der Erforschung von Impfstoffen gegen vermeidbare Krankheiten wie Geb\u00e4rmutterhalskrebs und andere HPV-bedingte Krebsarten. In der Schweiz arbeiten wir mit verschiedenen Partnern zusammen, um innovative L\u00f6sungen f\u00fcr die Krebsbehandlung voranzutreiben. In den letzten Jahren haben wir einen wichtigen Beitrag zur Verbesserung der Behandlungsm\u00f6glichkeiten f\u00fcr Krebspatient:innen geleistet.<\/p>\n\n\n\n

Hier<\/a> erfahren Sie mehr \u00fcber unsere Arbeit.<\/p>\n\n\n\n


<\/p>\n\n\n\n

CH-NON-01897, 10\/2025<\/sup><\/p>\n","protected":false},"excerpt":{"rendered":"

In der Schweiz wird jedes Jahr bei rund 6’600 Frauen und 60 M\u00e4nnern Brustkrebs diagnostiziert. Obwohl neue Therapien die Prognose von Brustkrebspatient:innen verbessert haben, sterben in der Schweiz immer noch rund 1\u2019400 Frauen pro Jahr an der Krankheit. \u00abWir stehen hinter den M\u00fcttern, Schwestern, T\u00f6chtern und Angeh\u00f6rigen, die von Brustkrebs betroffen sind, und setzen alles […]<\/p>\n","protected":false},"featured_media":7422,"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"footnotes":""},"tags":[17],"content_topic":[20],"admin_field":[],"class_list":["post-7373","story","type-story","status-publish","has-post-thumbnail","hentry","tag-responsibility","content_topic-our-people"],"yoast_head":"\nWir unterst\u00fctzen den Brustkrebsmonat Oktober I MSD Schweiz<\/title>\n<meta name=\"description\" content=\"Besonders im Brustkrebsmonat Oktober unterst\u00fctzt MSD Aktivit\u00e4ten, um \u00fcber die Bedeutung von Pr\u00e4vention und Fr\u00fcherkennung aufzukl\u00e4ren.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.msd.ch\/de\/stories\/wir-unterstutzen-den-brustkrebsmonat-oktober\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MSD unterst\u00fctzt den Brustkrebsmonat Oktober \ud83c\udf97\ufe0f\" \/>\n<meta property=\"og:description\" content=\"Besonders im Brustkrebsmonat Oktober unterst\u00fctzt MSD Aktivit\u00e4ten, um \u00fcber die Bedeutung von Pr\u00e4vention und Fr\u00fcherkennung aufzukl\u00e4ren.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.msd.ch\/de\/stories\/wir-unterstutzen-den-brustkrebsmonat-oktober\/\" \/>\n<meta property=\"og:site_name\" content=\"msd.ch\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-30T12:09:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2022\/09\/DSC00027_FlorianGraf_Photography_MSD_Pink_Ribbon_220925-2-e1664218873475.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2899\" \/>\n\t<meta property=\"og:image:height\" content=\"1830\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"MSD unterst\u00fctzt den Brustkrebsmonat Oktober \ud83c\udf97\ufe0f\" \/>\n<meta name=\"twitter:description\" content=\"Besonders im Brustkrebsmonat Oktober unterst\u00fctzt MSD Aktivit\u00e4ten, um \u00fcber die Bedeutung von Pr\u00e4vention und Fr\u00fcherkennung aufzukl\u00e4ren.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2022\/09\/DSC00027_FlorianGraf_Photography_MSD_Pink_Ribbon_220925-2-e1664218873475.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.msd.ch\/de\/stories\/wir-unterstutzen-den-brustkrebsmonat-oktober\/\",\"url\":\"https:\/\/www.msd.ch\/de\/stories\/wir-unterstutzen-den-brustkrebsmonat-oktober\/\",\"name\":\"Wir unterst\u00fctzen den Brustkrebsmonat Oktober I MSD Schweiz\",\"isPartOf\":{\"@id\":\"https:\/\/www.msd.ch\/de\/#website\"},\"datePublished\":\"2025-10-30T12:08:22+00:00\",\"dateModified\":\"2025-10-30T12:09:28+00:00\",\"description\":\"Besonders im Brustkrebsmonat Oktober unterst\u00fctzt MSD Aktivit\u00e4ten, um \u00fcber die Bedeutung von Pr\u00e4vention und Fr\u00fcherkennung aufzukl\u00e4ren.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.msd.ch\/de\/stories\/wir-unterstutzen-den-brustkrebsmonat-oktober\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.msd.ch\/de\/stories\/wir-unterstutzen-den-brustkrebsmonat-oktober\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.msd.ch\/de\/stories\/wir-unterstutzen-den-brustkrebsmonat-oktober\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Stories\",\"item\":\"https:\/\/www.msd.ch\/de\/stories-archive\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Wir unterst\u00fctzen den Brustkrebsmonat Oktober\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.msd.ch\/de\/#website\",\"url\":\"https:\/\/www.msd.ch\/de\/\",\"name\":\"msd.ch\",\"description\":\"MSD erforscht und entwickelt Medikamente und Impfstoffe, die Leben retten und die Gesundheit von Patienten verbessern sollen. In der Schweiz setzen sich 1000 Mitarbeitende in Luzern und Z\u00fcrich daf\u00fcr ein.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.msd.ch\/de\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Wir unterst\u00fctzen den Brustkrebsmonat Oktober I MSD Schweiz","description":"Besonders im Brustkrebsmonat Oktober unterst\u00fctzt MSD Aktivit\u00e4ten, um \u00fcber die Bedeutung von Pr\u00e4vention und Fr\u00fcherkennung aufzukl\u00e4ren.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.msd.ch\/de\/stories\/wir-unterstutzen-den-brustkrebsmonat-oktober\/","og_locale":"en_US","og_type":"article","og_title":"MSD unterst\u00fctzt den Brustkrebsmonat Oktober \ud83c\udf97\ufe0f","og_description":"Besonders im Brustkrebsmonat Oktober unterst\u00fctzt MSD Aktivit\u00e4ten, um \u00fcber die Bedeutung von Pr\u00e4vention und Fr\u00fcherkennung aufzukl\u00e4ren.","og_url":"https:\/\/www.msd.ch\/de\/stories\/wir-unterstutzen-den-brustkrebsmonat-oktober\/","og_site_name":"msd.ch","article_modified_time":"2025-10-30T12:09:28+00:00","og_image":[{"width":2899,"height":1830,"url":"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2022\/09\/DSC00027_FlorianGraf_Photography_MSD_Pink_Ribbon_220925-2-e1664218873475.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_title":"MSD unterst\u00fctzt den Brustkrebsmonat Oktober \ud83c\udf97\ufe0f","twitter_description":"Besonders im Brustkrebsmonat Oktober unterst\u00fctzt MSD Aktivit\u00e4ten, um \u00fcber die Bedeutung von Pr\u00e4vention und Fr\u00fcherkennung aufzukl\u00e4ren.","twitter_image":"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2022\/09\/DSC00027_FlorianGraf_Photography_MSD_Pink_Ribbon_220925-2-e1664218873475.jpg","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.msd.ch\/de\/stories\/wir-unterstutzen-den-brustkrebsmonat-oktober\/","url":"https:\/\/www.msd.ch\/de\/stories\/wir-unterstutzen-den-brustkrebsmonat-oktober\/","name":"Wir unterst\u00fctzen den Brustkrebsmonat Oktober I MSD Schweiz","isPartOf":{"@id":"https:\/\/www.msd.ch\/de\/#website"},"datePublished":"2025-10-30T12:08:22+00:00","dateModified":"2025-10-30T12:09:28+00:00","description":"Besonders im Brustkrebsmonat Oktober unterst\u00fctzt MSD Aktivit\u00e4ten, um \u00fcber die Bedeutung von Pr\u00e4vention und Fr\u00fcherkennung aufzukl\u00e4ren.","breadcrumb":{"@id":"https:\/\/www.msd.ch\/de\/stories\/wir-unterstutzen-den-brustkrebsmonat-oktober\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.msd.ch\/de\/stories\/wir-unterstutzen-den-brustkrebsmonat-oktober\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.msd.ch\/de\/stories\/wir-unterstutzen-den-brustkrebsmonat-oktober\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Stories","item":"https:\/\/www.msd.ch\/de\/stories-archive\/"},{"@type":"ListItem","position":2,"name":"Wir unterst\u00fctzen den Brustkrebsmonat Oktober"}]},{"@type":"WebSite","@id":"https:\/\/www.msd.ch\/de\/#website","url":"https:\/\/www.msd.ch\/de\/","name":"msd.ch","description":"MSD erforscht und entwickelt Medikamente und Impfstoffe, die Leben retten und die Gesundheit von Patienten verbessern sollen. In der Schweiz setzen sich 1000 Mitarbeitende in Luzern und Z\u00fcrich daf\u00fcr ein.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.msd.ch\/de\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"acf":[],"extended_data":{"featured_image":"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2022\/10\/Support-banner-stetoscope-e1664808142664.jpg?w=1024","acf_fields":{"mco_page_tracking_data":"","page_text_direction_selection":"ltr","show_section":true,"related_content_section_heading":"","story_one_selection":"select","related_content_item_one":{"ID":1433,"post_author":"974","post_date":"2026-02-20 11:55:56","post_date_gmt":"2026-02-20 10:55:56","post_content":"<!-- wp:acf\/hero-block {\"name\":\"acf\/hero-block\",\"data\":{\"mco_hero_block_tagline_text\":\"\",\"_mco_hero_block_tagline_text\":\"mco_hero_block_tagline_text\",\"mco_hero_block_ttle\":\"Onkologie\",\"_mco_hero_block_ttle\":\"mco_hero_block_title\",\"mco_hero_block_description\":\"Wir streben nach einer Welt, in der Krebs nicht nur behandelbar, sondern heilbar ist \u2013 und in der einige Arten sogar von vornherein verhindert werden k\u00f6nnen.\",\"_mco_hero_block_description\":\"mco_hero_block_description\",\"mco_hero_block_image_url\":1940,\"_mco_hero_block_image_url\":\"mco_hero_block_image_url\",\"mcc_hero_block_primary_image_alt\":\"\",\"_mcc_hero_block_primary_image_alt\":\"mcc_hero_block_primary_image_alt_text\",\"mco_hero_block_image_small_url\":\"\",\"_mco_hero_block_image_small_url\":\"mco_hero_block_image_small_url\",\"mcc_hero_block_secondary_image_alt\":\"\",\"_mcc_hero_block_secondary_image_alt\":\"mcc_hero_block_secondary_image_alt_text\",\"mco_hero_block_button_cta\":\"\",\"_mco_hero_block_button_cta\":\"mco_hero_block_button_cta\",\"hero_video_type\":\"youtube\",\"_hero_video_type\":\"hero_video_type\",\"youtube_video_url\":\"\",\"_youtube_video_url\":\"youtube_video\",\"video_accessible_name\":\"\",\"_video_accessible_name\":\"testimonial_video_accessible_name\",\"b2_hero_block_lazy_load_image\":\"0\",\"_b2_hero_block_lazy_load_image\":\"b2_hero_block_lazy_load_image_key\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:acf\/title-block {\"name\":\"acf\/title-block\",\"data\":{\"title\":\"Unser Ziel sind Innovationen, die das Leben von Menschen mit Krebs verl\u00e4ngern und verbessern\",\"_title\":\"mco_title_block_title\",\"description\":\"\\u003cdiv id=\\u0022mco-title-block-block_5e9de3bc8282f\\u0022 class=\\u0022mco-title-block msdberg-block mb-2 aligncenter\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022wrapper\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022mco-title-block-content\\u0022\\u003e\\r\\n\\r\\nWir arbeiten daran, Krebs durch Impfungen verhindern zu k\u00f6nnen und Onkolog:innen Behandlungsoptionen zu bieten, die ihren Patient:innen eine bessere Lebensqualit\u00e4t und mehr Zeit schenken.\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\nJeder kennt eine Person, die an Krebs erkrankt ist. Wenn eine Krebsdiagnose gestellt wird, ist es nicht wichtig, \\u003cem\\u003ewas\\u003c\/em\\u003e der n\u00e4chste wissenschaftliche Durchbruch ist, sondern \\u003cem\\u003ewann\\u003c\/em\\u003e er den Patient:innen in der Schweiz zur Verf\u00fcgung steht.\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_description\":\"mco_title_block_description\",\"content_label\":\"\",\"_content_label\":\"mco_title_block_content_label\",\"cta_one\":\"\",\"_cta_one\":\"mco_title_block_cta_one\",\"cta_two\":\"\",\"_cta_two\":\"mco_title_block_cta_two\",\"image\":\"\",\"_image\":\"mco_title_block_image\"},\"align\":\"center\",\"mode\":\"edit\"} \/-->\n\n<!-- wp:acf\/title-block {\"name\":\"acf\/title-block\",\"data\":{\"title\":\"Unsere Arbeit im Bereich Onkologie\",\"_title\":\"mco_title_block_title\",\"description\":\"\",\"_description\":\"mco_title_block_description\",\"content_label\":\"\",\"_content_label\":\"mco_title_block_content_label\",\"cta_one\":\"\",\"_cta_one\":\"mco_title_block_cta_one\",\"cta_two\":\"\",\"_cta_two\":\"mco_title_block_cta_two\",\"image\":\"\",\"_image\":\"mco_title_block_image\"},\"align\":\"center\",\"mode\":\"edit\",\"className\":\"pull-up-stats negative mb-2\"} \/-->\n\n<!-- wp:group {\"className\":\"stat-group mb-2\"} -->\n<div class=\"wp-block-group stat-group mb-2\"><!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"31\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"klinische Studien mit unseren Krebsmedikamenten in der Schweiz (Stand 01\/2026).\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"edit\",\"className\":\"mb-2\"} \/-->\n\n<!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"~250\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"Patient:innen nehmen derzeit an unseren klinischen Studien in der Schweiz teil, rund 120 erhalten das Studienmedikament (Stand 01\/2026).\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"edit\",\"className\":\"mb-2\"} \/-->\n\n<!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"\\u0026gt;15\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"verschiedene Krebsarten werden in unseren klinischen Studien in der Schweiz untersucht (Stand 01\/2026).\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"edit\",\"className\":\"mb-2\"} \/--><\/div>\n<!-- \/wp:group -->\n\n<!-- wp:columns {\"verticalAlignment\":\"top\"} -->\n<div class=\"wp-block-columns are-vertically-aligned-top\"><!-- wp:column {\"verticalAlignment\":\"top\",\"width\":\"32%\"} -->\n<div class=\"wp-block-column is-vertically-aligned-top\" style=\"flex-basis:32%\"><!-- wp:heading -->\n<h2 class=\"wp-block-heading\">Unser Fokus<\/h2>\n<!-- \/wp:heading --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column {\"verticalAlignment\":\"top\",\"width\":\"66.66%\"} -->\n<div class=\"wp-block-column is-vertically-aligned-top\" style=\"flex-basis:66.66%\"><!-- wp:paragraph -->\n<p>Unser Unternehmen blickt auf eine lange Geschichte der Entwicklung innovativer Medikamente zur\u00fcck. Im Bereich der Onkologie konzentrieren wir uns auf die Immuntherapie, die darauf abzielt, das k\u00f6rpereigene Immunsystem zur Bek\u00e4mpfung des Tumors zu aktivieren. Unser unerm\u00fcdliches Engagement in der Forschung und Entwicklung hat uns erm\u00f6glicht, ein aussergew\u00f6hnlich breit angelegtes Forschungsprogramm mit rund 1'600 klinischen Studien aufzubauen. Die Schweiz ist Teil dieses Programms, mit derzeit 31 <a href=\"https:\/\/www.msd.ch\/de\/home\/research\/clinical-trials\/clinical-trials-in-switzerland\/\">klinischen Studien<\/a> in verschiedenen Tumorarten (Stand 01\/2026). Heute umfasst unser Portfolio onkologische Medikamente f\u00fcr die Behandlung verschiedener Krebsarten und mit der Krebsbehandlung zusammenh\u00e4ngende Erkrankungen.<\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:columns {\"verticalAlignment\":\"top\"} -->\n<div class=\"wp-block-columns are-vertically-aligned-top\"><!-- wp:column {\"verticalAlignment\":\"top\",\"width\":\"32%\"} -->\n<div class=\"wp-block-column is-vertically-aligned-top\" style=\"flex-basis:32%\"><!-- wp:heading -->\n<h2 class=\"wp-block-heading\">Zugang zu medizinischer Versorgung<\/h2>\n<!-- \/wp:heading --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column {\"verticalAlignment\":\"top\",\"width\":\"66.66%\"} -->\n<div class=\"wp-block-column is-vertically-aligned-top\" style=\"flex-basis:66.66%\"><!-- wp:paragraph -->\n<p>Die Verbesserung des Zugangs zu Krebstherapien ist unsere strategische Zielsetzung. Wir arbeiten mit allen Akteuren im Bereich der Krebsversorgung zusammen, um Patient:innen den Zugang zu von ihnen ben\u00f6tigten onkologischen Medikamenten zu erleichtern und das Angebot an qualitativ hochwertigen Krebstherapien zu erweitern.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p><strong>Das Schweizer Onkologie-Team<\/strong>:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\"><!-- wp:list-item -->\n<li>arbeitet mit Beh\u00f6rden und Institutionen zusammen, um den Zugang zu unseren Medikamenten zu gew\u00e4hrleisten.<\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li>arbeitet an L\u00f6sungen, die medizinische Fachpersonen und Patient:innen kontinuierlich bei der Behandlung von Krebs unterst\u00fctzen k\u00f6nnen.<\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li>koordiniert die Zusammenarbeit mit Onkolog:innen, Wissenschaftsexpert:innen und Patientenorganisationen, um einen Einblick in die Markt- und Kundenbed\u00fcrfnisse zu erhalten.<\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li>informiert und ber\u00e4t sich mit Entscheidungstr\u00e4gern, wenn es darum geht, die Krebsversorgung in der Schweiz noch effizienter und l\u00f6sungsorientierter zu gestalten.<\/li>\n<!-- \/wp:list-item --><\/ul>\n<!-- \/wp:list --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:spacer {\"height\":\"35px\"} -->\n<div style=\"height:35px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">Fortschritt durch Partnerschaften<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column {\"width\":\"66.66%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:66.66%\"><!-- wp:paragraph -->\n<p>Wir arbeiten mit allen Akteuren im Bereich der Krebsversorgung zusammen: mit Interessengruppen, mit Dienstleistern im Gesundheitswesen, mit Regierungs- und Industriepartnern. Mit allen, die unsere Mission, das Leben von Menschen mit Krebs zu verl\u00e4ngern und zu verbessern, teilen.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p><strong>Unsere Schwerpunkte sind:<\/strong><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":9872,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\"} -->\n<figure class=\"wp-block-image size-large is-resized\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2023\/06\/education.png?w=240\" alt=\"\" class=\"wp-image-9872\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"level\":4} -->\n<h4 class=\"wp-block-heading\">Information und Fachwissen<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Wir stellen auf verschiedenen Plattformen Informationen \u00fcber Krebserkrankungen, Pr\u00e4vention und Fr\u00fcherkennung, Therapieoptionen und Hinweisen, wo Betroffene Rat und Unterst\u00fctzung bekommen, zur Verf\u00fcgung: f\u00fcr Krebspatient:innen und deren Angeh\u00f6rige sowie f\u00fcr medizinische Fachpersonen:<br><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\"><!-- wp:list-item -->\n<li><strong>meine-immuntherapie: <\/strong><br><a href=\"http:\/\/www.meine-immuntherapie.ch\" target=\"_blank\" rel=\"noreferrer noopener\">f\u00fcr Patient:innen unter Immuntherapie<\/a><br><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>msd-gesundheit.ch: <\/strong><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\">Informationsplattform f\u00fcr Krebspatient:innen<\/a> und deren Angeh\u00f6rige<br><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>mymsd.ch: <\/strong><a href=\"https:\/\/www.mymsd.ch\">Informationsplattform f\u00fcr medizinische Fachkreise<\/a><br><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>My Survival Story:<\/strong> <a href=\"https:\/\/www.mysurvivalstory.org\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Plattform f\u00fcr Betroffene, die ihre Krebserkrankung \u00fcberwunden haben<\/a><\/li>\n<!-- \/wp:list-item --><\/ul>\n<!-- \/wp:list --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":9873,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\"} -->\n<figure class=\"wp-block-image size-large is-resized\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2023\/06\/Prevention-1.png?w=240\" alt=\"\" class=\"wp-image-9873\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"level\":4} -->\n<h4 class=\"wp-block-heading\">Pr\u00e4vention und Fr\u00fcherkennung<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Wir arbeiten mit verschiedenen Patientenorganisationen zusammen und unterst\u00fctzen Kampagnen zur Sensibilisierung der Bev\u00f6lkerung \u00fcber die Pr\u00e4vention und Fr\u00fcherkennung von Krebs:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\"><!-- wp:list-item -->\n<li><strong>Derma2go<\/strong>: <a href=\"https:\/\/www.derma2go.com\/de\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">ein Schweizer Teledermatologie-Service, der Hautprobleme online von Fach\u00e4rzt:innen beurteilen l\u00e4sst und schnell eine fundierte Diagnose stellt<\/a><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>Leben mit Lungenkrebs: <\/strong><a href=\"https:\/\/www.leben-mit-lungenkrebs.ch\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Plattform f\u00fcr Lungenkrebspatient:innen und ihre Angeh\u00f6rigen<\/a><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>PINK CUBE Test Your Breast:<\/strong> <a href=\"https:\/\/www.pinkcube-testyourbreast.ch\" target=\"_blank\" rel=\"noreferrer noopener\">Initiative zur St\u00e4rkung der Brustkrebspr\u00e4vention und Fr\u00fcherkennung<\/a><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>SGDV <\/strong>Schweizerische Gesellschaft f\u00fcr Dermatologie und Venerologie: <a href=\"https:\/\/www.derma.swiss\/patienten\/hautkrebspraevention\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Nationale Hautkrebskampagne zur Pr\u00e4vention von Hautkrebs<\/a><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>Verein f\u00fcr Hautkrebsforschung<\/strong>: <a href=\"https:\/\/www.skincancer.ch\/\" target=\"_blank\" rel=\"noreferrer noopener\">Besch\u00e4ftigt sich mit der Forschung Pr\u00e4vention und Aufkl\u00e4rung \u00fcber Hautkrebs<\/a><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>Verein Lunge Z\u00fcrich<\/strong>: <a href=\"https:\/\/lunge-zuerich.ch\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">unterst\u00fctzt Menschen mit Lungenkrankheiten, informiert \u00fcber Lungengesundheit und setzt sich f\u00fcr Pr\u00e4vention und Fr\u00fcherkennung ein.<\/a><\/li>\n<!-- \/wp:list-item --><\/ul>\n<!-- \/wp:list --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":9874,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\"} -->\n<figure class=\"wp-block-image size-large is-resized\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2023\/06\/Cancer-care.png?w=240\" alt=\"\" class=\"wp-image-9874\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"level\":4} -->\n<h4 class=\"wp-block-heading\">Verbesserung der Krebsversorgung<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Wir unterst\u00fctzen Plattformen, die gesundheitspolitische Diskussionen zur Verbesserung der Krebsversorgung in der Schweiz kontinuierlich vorantreiben:<br><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\"><!-- wp:list-item -->\n<li><strong>Gfs Bern:<\/strong> <a href=\"https:\/\/www.msd.ch\/de\/news\/2-krebsversorgungsmonitor-der-schweiz-zeigt-krebsfruherkennung-fruhe-therapie-von-grosster-bedeutung\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">regelm\u00e4ssige Umfragen in der Bev\u00f6lkerung zur Qualit\u00e4t der Krebsversorgung der Schweiz<\/a><br><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>Oncosuisse: <\/strong>Wir sind Mitglied des Oncosuisse Partnerpools und f\u00f6rdern somit aktiv die Vernetzung der Stakeholder im Bereich der Krebsversorgung, die zum <a href=\"https:\/\/oncosuisse.ch\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Ziel hat, Barrieren im System abzubauen und L\u00fccken zu schliessen<\/a>.  <strong><br><\/strong><br><strong><br><\/strong><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>Schweizerisches Konsumentenforum kf: <\/strong>regelm\u00e4ssige OncoRoundtables mit verschiedenen Akteuren zur Diskussion und L\u00f6sungsfindung zur Verbesserung der aktuellen Krebsversorgung in der Schweiz.<br><\/li>\n<!-- \/wp:list-item --><\/ul>\n<!-- \/wp:list --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:acf\/testimonials-block {\"name\":\"acf\/testimonials-block\",\"data\":{\"media_placement\":\"left\",\"_media_placement\":\"testimonials_block_media_placement\",\"testimonials_posts\":[\"11857\"],\"_testimonials_posts\":\"testimonials_block_posts\"},\"mode\":\"preview\",\"className\":\"mb-1\"} \/-->\n\n<!-- wp:heading {\"textAlign\":\"center\"} -->\n<h2 class=\"wp-block-heading has-text-align-center\"><br>Haupttherapiebereiche<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:spacer {\"height\":\"30px\"} -->\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":11884,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2024\/11\/oncology_bladder.png?w=200\" alt=\"Ikone: Blasenkrebs\" class=\"wp-image-11884\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Blasenkrebs<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/blasenkrebs\">Informationen f\u00fcr Patient:innen<\/a><br><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/genitourinary-cancers\/uc\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informationen f\u00fcr Fachkreise<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":11878,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2024\/11\/Breast_icon-002.png?w=1163\" alt=\"Ikone: Brustkrebs\" class=\"wp-image-11878\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Brustkrebs<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/brustkrebs\" target=\"_blank\" rel=\"noreferrer noopener\">Informationen f\u00fcr Patient:innen<\/a><br><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/tnbc\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informationen f\u00fcr Fachkreise<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":11881,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2024\/11\/oncology_bowel.png?w=200\" alt=\"Ikone: Darmkrebs\" class=\"wp-image-11881\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Darmkrebs<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/darmkrebs\" target=\"_blank\" rel=\"noreferrer noopener\">Informationen f\u00fcr Patient:innen<\/a><br><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/gastrointestinal-cancers\/colorectal\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informationen f\u00fcr Fachkreise<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":13527,\"width\":\"100px\",\"height\":\"auto\",\"sizeSlug\":\"full\",\"linkDestination\":\"none\",\"align\":\"center\"} -->\n<figure class=\"wp-block-image aligncenter size-full is-resized\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2026\/01\/Icon_Biliary-Cancer.png\" alt=\"\" class=\"wp-image-13527\" style=\"width:100px;height:auto\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Gallenblasenkrebs<br>Gallengangskrebs<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/gallenblasenkrebs-und-gallengangskrebs\" target=\"_blank\" rel=\"noreferrer noopener\">Informationen f\u00fcr Patient:innen<\/a><br><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/gastrointestinal-cancers\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informationen f\u00fcr Fachkreise<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":11877,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2024\/11\/Keytruda_cervical-cancer_icon_msd_green-1.png?w=608\" alt=\"Ikone: Geb\u00e4rmutter-hals\/k\u00f6rper-Krebs\" class=\"wp-image-11877\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Geb\u00e4rmutterhalskrebs<br>Geb\u00e4rmutterk\u00f6rperkrebs<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informationen f\u00fcr Patient:innen<\/a><br><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/gyn-cancers\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informationen f\u00fcr Fachkreise<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":11883,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2024\/11\/oncology_lymphoma.png?w=200\" alt=\"Ikone: Hodgkin-Lymphom\" class=\"wp-image-11883\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Hodgkin-Lymphom<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/hodgkin-lymphom\" target=\"_blank\" rel=\"noreferrer noopener\">Informationen f\u00fcr Patient:innen<\/a><br><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/classical-hodgkin-lymphoma\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informationen f\u00fcr Fachkreise<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":11867,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"full\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-full is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2024\/11\/oncology_headneck1.png\" alt=\"Ikone: Kopf- und Halskrebs\" class=\"wp-image-11867\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Kopf- und Halskrebs<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/kopf-und-halskrebs\" target=\"_blank\" rel=\"noreferrer noopener\">Informationen f\u00fcr Patient:innen<\/a><br><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/head-and-neck-squamous-cell-carcinoma\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informationen f\u00fcr Fachkreise<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":11880,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2024\/11\/oncology_lung.png?w=200\" alt=\"Ikone: Lungenkrebs\" class=\"wp-image-11880\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Lungenkrebs<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/lungenkrebs\" target=\"_blank\" rel=\"noreferrer noopener\">Informationen f\u00fcr Patient:innen<\/a><br><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/tc\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informationen f\u00fcr Fachkreise<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":12632,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"full\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-full is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2025\/08\/Icon-Magenkrebs.png\" alt=\"\" class=\"wp-image-12632\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Magenkrebs<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/magenkrebs\" target=\"_blank\" rel=\"noreferrer noopener\">Informationen f\u00fcr Patient:innen<\/a><br><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/gastrointestinal-cancers\/gastric\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informationen f\u00fcr Fachkreise<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":11882,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2024\/11\/oncology_melanoma.png?w=200\" alt=\"Ikone: Melanom\" class=\"wp-image-11882\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Melanom<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/melanom\" target=\"_blank\" rel=\"noreferrer noopener\">Informationen f\u00fcr Patient:innen<\/a><br><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/melanom\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informationen f\u00fcr Fachkreise<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":11879,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2024\/11\/Prostate-Cancer-Icon.png?w=161\" alt=\"Ikone: Prostatakrebs\" class=\"wp-image-11879\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Prostatakrebs<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/prostatakrebs\">Informationen f\u00fcr Patient:innen<\/a><br><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":11876,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2024\/11\/oncology_kidney.png?w=200\" alt=\"Ikone: Nierenkrebs\" class=\"wp-image-11876\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Nierenkrebs<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/nierenkrebs\">Informationen f\u00fcr Patient:innen<\/a><br><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/genitourinary-cancers\/rcc\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informationen f\u00fcr Fachkreise<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:spacer {\"height\":\"45px\"} -->\n<div style=\"height:45px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer -->\n\n<!-- wp:acf\/title-block {\"name\":\"acf\/title-block\",\"data\":{\"title\":\"Lesen Sie mehr \u00fcber unser Engagement zur Bek\u00e4mpfung von Krebs\",\"_title\":\"mco_title_block_title\",\"description\":\"\",\"_description\":\"mco_title_block_description\",\"content_label\":\"\",\"_content_label\":\"mco_title_block_content_label\",\"cta_one\":\"\",\"_cta_one\":\"mco_title_block_cta_one\",\"cta_two\":\"\",\"_cta_two\":\"mco_title_block_cta_two\",\"image\":\"\",\"_image\":\"mco_title_block_image\"},\"align\":\"center\",\"mode\":\"edit\",\"className\":\"mt-2\"} \/-->\n\n<!-- wp:acf\/featured-stories-block-e1 {\"name\":\"acf\/featured-stories-block-e1\",\"data\":{\"content_selection\":\"manual\",\"_content_selection\":\"mco_featured_stories_e1_block_content_selection\",\"story_one\":8326,\"_story_one\":\"mco_featured_stories_e1_block_story_one\",\"story_two\":10975,\"_story_two\":\"mco_featured_stories_e1_block_story_two\",\"story_three\":10010,\"_story_three\":\"mco_featured_stories_e1_block_story_three\",\"story_four\":7494,\"_story_four\":\"mco_featured_stories_e1_block_story_four\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:paragraph -->\n<p><sup>CH-NON-00473, 02\/2026<\/sup><\/p>\n<!-- \/wp:paragraph -->","post_title":"Onkologie","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"oncology","to_ping":"","pinged":"","post_modified":"2026-02-20 11:56:07","post_modified_gmt":"2026-02-20 10:56:07","post_content_filtered":"","post_parent":25,"guid":"https:\/\/vip2-msd.com\/germany\/?page_id=1433","menu_order":0,"post_type":"page","post_mime_type":"","comment_count":"0","filter":"raw"},"story_two_selection":"select","related_content_item_two":{"ID":2759,"post_author":"974","post_date":"2026-03-31 21:02:02","post_date_gmt":"2026-03-31 19:02:02","post_content":"<!-- wp:acf\/hero-block {\"name\":\"acf\/hero-block\",\"data\":{\"mco_hero_block_tagline_text\":\"\",\"_mco_hero_block_tagline_text\":\"mco_hero_block_tagline_text\",\"mco_hero_block_ttle\":\"Klinische Studien von MSD in der Schweiz\",\"_mco_hero_block_ttle\":\"mco_hero_block_title\",\"mco_hero_block_description\":\"\u201cKlinische Studien sind der Schl\u00fcssel zu neuen Erkenntnissen in der Diagnostik und Therapie von Erkrankungen. Wir sind stolz, in der Schweiz dazu beizutragen.\\u0022\\r\\n\\r\\n\\u003cem\\u003eKlaudia Georgi, Sr. Director Clinical Research MSD Switzerland \\u0026amp; Serbia\\u003c\/em\\u003e\",\"_mco_hero_block_description\":\"mco_hero_block_description\",\"mco_hero_block_image_url\":2760,\"_mco_hero_block_image_url\":\"mco_hero_block_image_url\",\"mcc_hero_block_primary_image_alt\":\"\",\"_mcc_hero_block_primary_image_alt\":\"mcc_hero_block_primary_image_alt_text\",\"mco_hero_block_image_small_url\":\"\",\"_mco_hero_block_image_small_url\":\"mco_hero_block_image_small_url\",\"mcc_hero_block_secondary_image_alt\":\"\",\"_mcc_hero_block_secondary_image_alt\":\"mcc_hero_block_secondary_image_alt_text\",\"mco_hero_block_button_cta\":{\"title\":\"Grundwissen Klinische Studien\",\"url\":\"https:\/\/www.msd.ch\/de\/home\/research\/clinical-trials\/\",\"target\":\"\"},\"_mco_hero_block_button_cta\":\"mco_hero_block_button_cta\",\"mco_hero_block_button_cta_aria_label\":\"\",\"_mco_hero_block_button_cta_aria_label\":\"mco_hero_block_button_cta_aria_label\",\"hero_video_type\":\"youtube\",\"_hero_video_type\":\"hero_video_type\",\"youtube_video_url\":\"\",\"_youtube_video_url\":\"youtube_video\",\"video_accessible_name\":\"\",\"_video_accessible_name\":\"testimonial_video_accessible_name\",\"b2_hero_block_lazy_load_image\":\"0\",\"_b2_hero_block_lazy_load_image\":\"b2_hero_block_lazy_load_image_key\"},\"mode\":\"preview\"} \/-->\n\n<!-- wp:acf\/title-block {\"name\":\"acf\/title-block\",\"data\":{\"title\":\"Unsere Arbeit in Zahlen\",\"_title\":\"mco_title_block_title\",\"description\":\"\",\"_description\":\"mco_title_block_description\",\"content_label\":\"\",\"_content_label\":\"mco_title_block_content_label\",\"cta_one\":\"\",\"_cta_one\":\"mco_title_block_cta_one\",\"cta_two\":\"\",\"_cta_two\":\"mco_title_block_cta_two\",\"image\":\"\",\"_image\":\"mco_title_block_image\"},\"align\":\"center\",\"mode\":\"preview\",\"className\":\"pull-up-stats negative mb-2\"} \/-->\n\n<!-- wp:group -->\n<div class=\"wp-block-group\"><!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"40\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"Laufende klinische Studien in der Schweiz\\r\\n(Stand 01\/2026)\\r\\n\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"preview\"} \/-->\n\n<!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"10\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"In der Schweiz zugelassene First-in-Class-Medikamente und Impfstoffe seit 2000\\r\\n(Stand 01\/2026)\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"preview\"} \/-->\n\n<!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"173\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"Millionen Schweizer Franken in die Forschung investiert, seit 2012 \\r\\n(Stand 01\/2026)\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"preview\"} \/--><\/div>\n<!-- \/wp:group -->\n\n<!-- wp:acf\/content-block {\"name\":\"acf\/content-block\",\"data\":{\"maintain_image_aspect_ratio\":\"0\",\"_maintain_image_aspect_ratio\":\"content_block_maintain_image_aspect_ratio\",\"negative_style\":\"0\",\"_negative_style\":\"content_block_negative\",\"content_selection\":\"static\",\"_content_selection\":\"content_selction_method\",\"content_block_image\":13898,\"_content_block_image\":\"content_block_image\",\"content_block_heading\":\"Die klinische Forschung von MSD Schweiz wird in unserer Niederlassung in der R\u00f6sslimatt in Luzern koordiniert.\",\"_content_block_heading\":\"content_block_heading\",\"heading_level\":\"h3\",\"_heading_level\":\"content_block_heading_level\",\"content_block_body\":\"\",\"_content_block_body\":\"content_block_body\",\"content_block_cta\":{\"title\":\"Unsere Niederlassungen\",\"url\":\"https:\/\/www.msd.ch\/de\/home\/about-us\/sites\/\",\"target\":\"_blank\"},\"_content_block_cta\":\"content_block_cta\",\"content_block_aria_label\":\"\",\"_content_block_aria_label\":\"content_block_aria_label\",\"content_block_cta_button_style\":\"\",\"_content_block_cta_button_style\":\"content_block_cta_button_style_cf4f3fd32dc26ec4ba7a6c14e51289c8\",\"content_block_optional_cta\":\"\",\"_content_block_optional_cta\":\"content_block_optional_cta\",\"content_block_optional_cta_aria_label\":\"\",\"_content_block_optional_cta_aria_label\":\"content_block_optional_cta_aria_label\",\"content_block_optional_cta_button_style\":\"\",\"_content_block_optional_cta_button_style\":\"content_block_optional_cta_button_style_d7b3517ac72218a3fb8daa4bc7def7a4\",\"content_block_optional_tag\":\"\",\"_content_block_optional_tag\":\"content_block_optional_tag\",\"content_block_video\":\"\",\"_content_block_video\":\"content_block_video\",\"content_media_position\":\"left\",\"_content_media_position\":\"content_media_position\",\"brightcove_account_id\":\"\",\"_brightcove_account_id\":\"bright_cove_account_id\",\"content_block_video_accessible_name\":\"\",\"_content_block_video_accessible_name\":\"content_block_video_accessible_name\",\"content_block_play_button_accessible_name\":\"\",\"_content_block_play_button_accessible_name\":\"content_block_play_button_accessible_name\",\"content_block_popup_accessible_name\":\"\",\"_content_block_popup_accessible_name\":\"content_block_popup_accessible_name\",\"content_block_popup_close_button_accessible_name\":\"\",\"_content_block_popup_close_button_accessible_name\":\"content_block_popup_close_button_accessible_name\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":1} -->\n<h1 class=\"wp-block-heading has-text-align-center\">Das klinische Studienprogramm von MSD in der Schweiz (Stand 01\/2026)<\/h1>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\"} -->\n<p class=\"has-text-align-center\">(ver\u00f6ffentlicht auf <a href=\"http:\/\/www.clinicaltrials.gov\">www.clinicaltrials.gov<\/a>)<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":13485,\"sizeSlug\":\"full\",\"linkDestination\":\"none\",\"className\":\"mb-2\"} -->\n<figure class=\"wp-block-image size-full mb-2\"><img src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2026\/01\/2026-01-MSD-Karte-Klinische-Studienprogramm-Schweiz.png\" alt=\"Karte: Standorte Klinische Studie MSD Schweiz (Stand 01\/2026)\" class=\"wp-image-13485\"\/><\/figure>\n<!-- \/wp:image --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:acf\/b6-accordion-list {\"name\":\"acf\/b6-accordion-list\",\"data\":{\"mco_b6_accordion_list_tagline\":\"\",\"_mco_b6_accordion_list_tagline\":\"mco_b6_accordion_list_tagline_6947uhf9ywhuj\",\"mco_b6_accordion_list_title\":\"Im Bereich Allgemeinmedizin\",\"_mco_b6_accordion_list_title\":\"mco_b6_accordion_list_title_6947uhf9ywhuj\",\"mco_b6_accordion_type\":\"multiple\",\"_mco_b6_accordion_type\":\"mco_b6_accordion_type_6947uhf9ywhuj\",\"mco_b6_accordion_list_collapse_button\":\"1\",\"_mco_b6_accordion_list_collapse_button\":\"mco_b6_accordion_expand_all_6947uhf9ywhuj\",\"mco_b6_accordion_expand_all\":\"Alle aufklappen\",\"_mco_b6_accordion_expand_all\":\"mco_b6_accordion_expand_all\",\"mco_b6_accordion_close_all\":\"Alle schliessen\",\"_mco_b6_accordion_close_all\":\"mco_b6_accordion_close\",\"mco_b6_accordion_add_faq\":\"1\",\"_mco_b6_accordion_add_faq\":\"mco_b6_accordion_add_faq\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"Lungenkrankheit\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-5475-013 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease\\r\\n\\r\\nStudy centers: St. Gallen, Zurich, Basel\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-7962-038 \u2013 Study in start-up\\u003c\/strong\\u003e\\r\\n\\r\\nAn Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH\\r\\n\\r\\nStudy center: Zurich\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row\":1,\"_mco_b6_accordion_list_row\":\"mco_b6_accordion_list_row_6947uhf9ywhuj\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:acf\/b6-accordion-list {\"name\":\"acf\/b6-accordion-list\",\"data\":{\"mco_b6_accordion_list_tagline\":\"\",\"_mco_b6_accordion_list_tagline\":\"mco_b6_accordion_list_tagline_6947uhf9ywhuj\",\"mco_b6_accordion_list_title\":\"Im Bereich Immunologie\",\"_mco_b6_accordion_list_title\":\"mco_b6_accordion_list_title_6947uhf9ywhuj\",\"mco_b6_accordion_type\":\"multiple\",\"_mco_b6_accordion_type\":\"mco_b6_accordion_type_6947uhf9ywhuj\",\"mco_b6_accordion_list_collapse_button\":\"1\",\"_mco_b6_accordion_list_collapse_button\":\"mco_b6_accordion_expand_all_6947uhf9ywhuj\",\"mco_b6_accordion_expand_all\":\"Alle aufklappen\",\"_mco_b6_accordion_expand_all\":\"mco_b6_accordion_expand_all\",\"mco_b6_accordion_close_all\":\"Alle schliessen\",\"_mco_b6_accordion_close_all\":\"mco_b6_accordion_close\",\"mco_b6_accordion_add_faq\":\"1\",\"_mco_b6_accordion_add_faq\":\"mco_b6_accordion_add_faq\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"Darmkrankheit\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-7240-001 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Ulcerative Colitis\\r\\n\\r\\nStudy centers: Bern, St. Gallen, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-7240-008 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Crohn\u2019s Disease\\r\\n\\r\\nStudy centers: Basel, Bern, St. Gallen, Zurich\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row\":1,\"_mco_b6_accordion_list_row\":\"mco_b6_accordion_list_row_6947uhf9ywhuj\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:acf\/b6-accordion-list {\"name\":\"acf\/b6-accordion-list\",\"data\":{\"mco_b6_accordion_list_tagline\":\"\",\"_mco_b6_accordion_list_tagline\":\"mco_b6_accordion_list_tagline_6947uhf9ywhuj\",\"mco_b6_accordion_list_title\":\"Im Bereich Infektiologie\",\"_mco_b6_accordion_list_title\":\"mco_b6_accordion_list_title_6947uhf9ywhuj\",\"mco_b6_accordion_type\":\"multiple\",\"_mco_b6_accordion_type\":\"mco_b6_accordion_type_6947uhf9ywhuj\",\"mco_b6_accordion_list_collapse_button\":\"1\",\"_mco_b6_accordion_list_collapse_button\":\"mco_b6_accordion_expand_all_6947uhf9ywhuj\",\"mco_b6_accordion_expand_all\":\"Alle aufklappen\",\"_mco_b6_accordion_expand_all\":\"mco_b6_accordion_expand_all\",\"mco_b6_accordion_close_all\":\"Alle schliessen\",\"_mco_b6_accordion_close_all\":\"mco_b6_accordion_close\",\"mco_b6_accordion_add_faq\":\"1\",\"_mco_b6_accordion_add_faq\":\"mco_b6_accordion_add_faq\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"HIV\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-8527-011 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nPhase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis\\r\\n\\r\\nStudy centers: Basel, Bern, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-8591A-051 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\nA Phase 3, Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine\/Islatravir (DOR\/ISL 100 mg\/0.25 mg) Once-Daily in Participants With HIV-1 Who Are Virologically Suppressed on Antiretroviral Therapy\\r\\n\\r\\nStudy centers: Basel, Bern, Geneva, Lausanne, Lugano, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cstrong\\u003eMK-8591A-053 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine\/Islatravir (DOR\/ISL 100 mg\/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Na\u00efve Participants\\r\\n\\r\\nStudy centers: Basel, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-8591A-054 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3 Open-label Clinical Study of Doravirine\/Islatravir (DOR\/ISL [100 mg\/0.25 mg]) Once Daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR\/ISL (100 mg\/0.75 mg) QD in a Phase 3 Clinical Study\\r\\n\\r\\nStudy centers: Basel, Bern, Geneva, St. Gallen, Lugano, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cstrong\\u003eMK-8591B-060 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 2b, Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Islatravir (ISL) and Ulonivirine (ULO) Once-Weekly in Adults with HIV-1 Virologically Suppressed on Bictegravir\/Emtricitabine\/Tenofovir Alafenamide (BIC\/FTC\/TAF) Once-Daily\\r\\n\\r\\nStudy centers: Basel, Bern, Geneva, Lugano\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row\":1,\"_mco_b6_accordion_list_row\":\"mco_b6_accordion_list_row_6947uhf9ywhuj\"},\"mode\":\"edit\",\"className\":\"mt-2\"} \/-->\n\n<!-- wp:acf\/b6-accordion-list {\"name\":\"acf\/b6-accordion-list\",\"data\":{\"mco_b6_accordion_list_tagline\":\"\",\"_mco_b6_accordion_list_tagline\":\"mco_b6_accordion_list_tagline_6947uhf9ywhuj\",\"mco_b6_accordion_list_title\":\"Im Bereich Onkologie\",\"_mco_b6_accordion_list_title\":\"mco_b6_accordion_list_title_6947uhf9ywhuj\",\"mco_b6_accordion_type\":\"multiple\",\"_mco_b6_accordion_type\":\"mco_b6_accordion_type_6947uhf9ywhuj\",\"mco_b6_accordion_list_collapse_button\":\"1\",\"_mco_b6_accordion_list_collapse_button\":\"mco_b6_accordion_expand_all_6947uhf9ywhuj\",\"mco_b6_accordion_expand_all\":\"Alle aufklappen\",\"_mco_b6_accordion_expand_all\":\"mco_b6_accordion_expand_all\",\"mco_b6_accordion_close_all\":\"Alle schliessen\",\"_mco_b6_accordion_close_all\":\"mco_b6_accordion_close\",\"mco_b6_accordion_add_faq\":\"1\",\"_mco_b6_accordion_add_faq\":\"mco_b6_accordion_add_faq\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"Blasenkrebs\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-676\/KEYNOTE-676 - recruitment closed\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eA Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HRNMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Basel, Geneva, Zurich\\u003c\/p\\u003e\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_summary\":\"Blutkrebs (H\u00e4matologische Malignome)\",\"_mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_1_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_1_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_1_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_1_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-1026-003 - recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies\\r\\n\\r\\nStudy centers: Bellinzona, Bern\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2140-010 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)\\r\\n\\r\\nStudy centers: Baden, Bellinzona, St. Gallen\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-4280A-008 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician\u2019s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)\\r\\n\\r\\nStudy centers: Bellinzona\",\"_mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_summary\":\"Brustkrebs\",\"_mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_2_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_2_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_2_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_2_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-2870-010 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nAn Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician`s Choice in Participants with HR+\/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer\\r\\n\\r\\nStudy centers: Basel, Thun, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2870-012 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician\u2019s Choice in Participants With Triple Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) At Surgery\\r\\n\\r\\nStudy centers: Chur, Fribourg, Geneva, Thun, Zurich\",\"_mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_summary\":\"Gyn\u00e4kologische Krebserkrankungen\",\"_mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_3_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_3_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_3_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_3_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-2870-005 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician\u2019s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy\\r\\n\\r\\nStudy centers: Bern, Bellinzona, Chur, Basel\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2870-020 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician\u2019s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer\\r\\n\\r\\nStudy centers: Basel, Bern\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2870-021 \u2013 Study in start-up\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021\/ENGOTov85\/GOG-3102)\\r\\n\\r\\nStudy centers: Bern, Bellinzona, Chur, Geneva, Winterthur\",\"_mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_summary\":\"Kopf- und Halskrebs\",\"_mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_4_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_4_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_4_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_4_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-689\/KEYNOTE-689 \u2013 recruitment closed\\u003c\/strong\\u003e\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\nA Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)\\r\\n\\r\\nStudy center: Geneva\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_summary\":\"Lungenkrebs\",\"_mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_5_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_5_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_5_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_5_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-1084-007 \u2013 Study in start-up\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed\/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)\\r\\n\\r\\nStudy centers: Fribourg, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2870-019 \u2013 \\u003cspan class=\\u0022gray_text\\u0022\\u003erecruitment open\\u003c\/span\\u003e\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3 Randomized Open-label Study of Adjuvant Pembrolizumab with or without MK-2870 in Resectable Stages II-IIIB (N2) NSCLC for participants not achieving pCR after Receiving Neoadjuvant Pembrolizumab with Platinum-based Doublet Chemotherapy Followed by Surgery\\r\\n\\r\\nStudy centers: Lausanne, Fribourg, Frauenfeld, Chur\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-091\/KEYNOTE-091 -\u00a0\\u003cspan class=\\u0022gray_text\\u0022\\u003eoutsourced - recruitment closed\\u003c\/span\\u003e\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eA randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Basel, Bellinzona, Bern, Chur, Geneva, Lausanne, Lucerne, St. Gallen, Winterthur, Zurich\\u003c\/p\\u003e\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-B98 - recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eA Phase 1b\/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1\/L1-refactory Extensive Stage Small Cell Lung Cancer in Need of Second-Line Therapy\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy center: St. Gallen\\u003c\/p\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_summary\":\"Magenkrebs\",\"_mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_6_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_6_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_6_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_6_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-1022-011 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers\\r\\n\\r\\nStudy centers: Geneva, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003e\\u003cstrong\\u003eMK-5909-005 \u2013 recruitment open\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\nA Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers\\r\\n\\r\\nStudy centers: Basel, Zurich, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-9999-U02A \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Substudy of the MK-9999-U02 Master Protocol to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers\\r\\n\\r\\nStudy centers: Bellinzona, Geneva\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_summary\":\"Melanom (Schwarzer Hautkrebs)\",\"_mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_7_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_7_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_7_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_7_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-054 \/ KEYNOTE-054 - \\u003cspan class=\\u0022gray_text\\u0022\\u003eoutsourced - recruitment closed\\u003c\/span\\u003e\\u003c\/strong\\u003e\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Geneva, Zurich\\u003c\/p\\u003e\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-716\/KEYNOTE-716 -\u00a0\\u003cspan class=\\u0022green_text\\u0022\\u003erecruitment closed\\u003c\/span\\u003e\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eAdjuvant Therapy with Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Bellinzona, Bern, Chur, Geneva, Lausanne, Sion, St. Gallen, Zurich\\u003c\/p\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_summary\":\"Nierenkrebs (Nierenzellkarzinom)\",\"_mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_8_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_8_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_8_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_8_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_details\":\"\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-6482-011 - recruitment closed\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eAn Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1\/L1 Therapy\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Bellinzona, Chur, Geneva, Zurich\\u003c\/p\\u003e\",\"_mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_summary\":\"Prostatakrebs\",\"_mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_9_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_9_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_9_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_9_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-2400-001 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)\\r\\n\\r\\nStudy centers: Aarau, Basel, Fribourg, Geneva, Zurich\",\"_mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_summary\":\"Solide Tumore\",\"_mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_10_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_10_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_10_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_10_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-0472-001 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants with Advanced\/Metastatic Solid Tumors.\\r\\n\\r\\nStudy centers: Geneva, Bellinzona, St. Gallen\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-1084-001 - recruitment open\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\nA Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors\\r\\n\\r\\nStudy centers: Bellinzona, St. Gallen\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u0026nbsp;\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-587\/KEYNOTE-587 - recruitment closed\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eLong-term Safety and Efficacy Extension Study for Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy center: Basel, Geneva, Zurich\\u003c\/p\\u003e\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-4884-001 \u2013 Study in start-up\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1 Open-label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-4884 in Participants with Advanced Solid Tumors\\r\\n\\r\\nStudy centers: Bellinzona, Lausanne, St. Gallen\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-7339-002 - recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eA Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy center: Bellinzona\\u003c\/p\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_summary\":\"Speiser\u00f6hrenkrebs\",\"_mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_11_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_11_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_11_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_11_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-3475-06B \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1\/PD-L1 Treatment: Substudy 06B.\\r\\n\\r\\nStudy centers: Chur, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-06C \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Open-Label, Umbrella Platform Design Study of MK-2870 With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable\/ Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma): Substudy 06C\\r\\n\\r\\nStudy centers: Chur, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-06D \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of MK-2870 Plus Paclitaxel as the Second-Line Treatment of Participants With Advanced\/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D\\r\\n\\r\\nStudy centers: Chur, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-06E \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable\/Metastatic Esophageal Cancer: Substudy 06E\\r\\n\\r\\nStudy centers: Chur, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-06F \u2013 Study in start-up \\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L\/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: Substudy 06F\\r\\n\\r\\nStudy centers: Chur, Geneva\",\"_mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row\":12,\"_mco_b6_accordion_list_row\":\"mco_b6_accordion_list_row_6947uhf9ywhuj\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:paragraph -->\n<p>Zur \u00dcbersicht der schweizweiten Studien, die Teilnehmende suchen, <a href=\"https:\/\/www.humanforschung-schweiz.ch\/de\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">www.humanforschung-schweiz.ch<\/a><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:acf\/featured-banner-block {\"name\":\"acf\/featured-banner-block\",\"data\":{\"mco_featured_banner_negative\":\"1\",\"_mco_featured_banner_negative\":\"mco_featured_banner_negative_294ytohe\",\"image\":2806,\"_image\":\"mco_featured_banner_block_image\",\"title\":\"Wir m\u00f6chten Menschen mit Krebs Hoffnung schenken\",\"_title\":\"mco_featured_banner_block_title\",\"description\":\"Wir investieren in die Entwicklung innovativer onkologischer Medikamente, um Menschen mit Krebserkrankungen zu helfen.\",\"_description\":\"mco_featured_banner_block_description\",\"content_label\":\"\",\"_content_label\":\"mco_featured_banner_block_content_label\",\"cta_one\":{\"title\":\"Mehr erfahren\",\"url\":\"https:\/\/www.msd.ch\/de\/about-msd\/areas-of-focus\/oncology\/\",\"target\":\"_blank\"},\"_cta_one\":\"mco_featured_banner_block_cta_one\",\"cta_two\":\"\",\"_cta_two\":\"mco_featured_banner_block_cta_two\"},\"mode\":\"preview\"} \/-->\n\n<!-- wp:paragraph -->\n<p><sup>CH-NON-00136, 03\/2026<\/sup><\/p>\n<!-- \/wp:paragraph -->","post_title":"Klinische Studien von MSD in der Schweiz","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"clinical-trials-in-switzerland","to_ping":"","pinged":"","post_modified":"2026-03-31 21:02:15","post_modified_gmt":"2026-03-31 19:02:15","post_content_filtered":"","post_parent":13045,"guid":"https:\/\/vip2-msd.com\/switzerland\/?page_id=2759","menu_order":1,"post_type":"page","post_mime_type":"","comment_count":"0","filter":"raw"},"story_three_selection":"select","related_content_item_three":false,"scroll-to-top":false,"subheader_title":"Wussten Sie, dass Brustkrebs die h\u00e4ufigste Krebsart bei Frauen ist? Bei MSD zeigen wir Solidarit\u00e4t mit Menschen, die von Brustkrebs betroffen sind, und tun alles, was wir k\u00f6nnen, um weitere Fortschritte bei der Bek\u00e4mpfung der Krankheit zu unterst\u00fctzen. Insbesondere w\u00e4hrend des Brustkrebsmonats Oktober unterst\u00fctzen wir verschiedene Aktivit\u00e4ten, um \u00fcber die Bedeutung von Pr\u00e4vention und Fr\u00fcherkennung aufzukl\u00e4ren. Erfahren Sie mehr \u00fcber unser Engagement.","secondary_image":false,"video_hosting_selection":"youtube","youtube_url":"","primary_cta":"Read more","secondary_cta":"","mcc_page_job_number":"","show_image_captions":false,"heading_level":"","related_content_item_one_aria_label":"","related_content_item_two_aria_label":"","video_accessible_name":"","primary_cta_aria_label":"","secondary_cta_aria_label":""}},"_links":{"self":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/story\/7373","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/story"}],"about":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/types\/story"}],"version-history":[{"count":17,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/story\/7373\/revisions"}],"predecessor-version":[{"id":12818,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/story\/7373\/revisions\/12818"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/media\/7422"}],"wp:attachment":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/media?parent=7373"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/tags?post=7373"},{"taxonomy":"content_topic","embeddable":true,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/content_topic?post=7373"},{"taxonomy":"Admin Field","embeddable":true,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/admin_field?post=7373"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}